MetaCap

Altimmune (ALT) vs Galectin Therapeutics (GALT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Galectin Therapeutics (GALT) has outperformed Altimmune (ALT) over the past year, losing 49.7% versus a loss of 72.3%. Over five years, GALT leads with a +4.7% price change compared with -87.2% for ALT. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $258.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-72.35%GALT-49.72%
+34%-22%-77%
Nov 21, 20251 yearNov 20, 2026
ALT-87.39%GALT0.00%
+143%+22%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus GALT key metrics
MetricALTGALT
Share price$1.33$2.69
Market cap$258.80M$271.35M
1-day change-5.67%-4.27%
YTD return-63.16%-35.34%
1-year return-72.35%-49.72%
5-year return-87.24%+4.67%
EPS (TTM)$-0.71$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K—
Revenue growth (YoY)+105.00%—
Net income (latest FY)$-88.09M$-30.84M
Operating margin-230460.98%—
Net margin-214860.98%—
52-week high$6.44$7.13
52-week low$1.32$2.03
Distance from 52-week high-79.35%-62.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1127.82%+308.92%
Average volume3.91M252.31K
Shares outstanding194.59M100.88M
Employees579
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GALT has outperformed ALT by 22.6 percentage points over the past year.

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

ALT vs GALT FAQ

Which is bigger, Altimmune or Galectin Therapeutics?

Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $258.80M for Altimmune (ALT).

Which stock has performed better over the past year, ALT or GALT?

GALT returned -49.72% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.

Are Altimmune and Galectin Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons